Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net
EU-kommissionen har godkänt sanofi-aventis läkemedel Taxotere (docetaxel) för adjuvant behandling, det vill säga direkt efter operation, vid tidig körtelpositiv bröstcancer. Kommissionens beslut baseras på resultatet av en stor långtidsstudie som visar på både en ökad överlevnad och minskad risk för återfall vid behandling med Taxotere. - Detta är framsteg vad gäller bröstcancerbehandling. Resu
Sanofi-aventis organizes today, January 25, 2005, a solidarity day in 300 sanofi-aventis sites worldwide to allow Group collaborators to take part in actions undertaken with partner aid agencies in the tsunami-stricken countries. Each employee will be able to share in the movement of solidarity by opting, either to make financial donation to the projects of the villages twinned with his or her
Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look
Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites. Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursua
According to a decision by the European Commission announced today, various producers of MCAA (monochloroacetic acid), an organic chemical used as intermediate in the manufacture of various products, have been fined. This decision was made further to an investigation regarding alleged arrangements affecting competition in certain markets for MCAA. Among those producers, Hoechst, an affiliate of
Sanofi-aventis announced today that the European Commission has approved 2 new indications for Taxotere® (docetaxel) Injection Concentrate for treatment of breast cancer. The first granted TAXOTERE , in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer. A second granted TAXOTERE , in combination with Herceptin (tr
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that, following a review of the Vascular Endothelial Growth Factor (VEGF) Trap program, they have reaffirmed their commitment to develop the VEGF Trap in oncology in collaboration with Regeneron Pharmaceuticals Inc. (Nasdaq: REGN). The companies will evaluate the VEGF Trap in a variety of cancer types, both in single-agent studies and in
Sanofi-aventis announced today the official change in the legal denomination of the Aventis Pasteur company, which will henceforth be named sanofi pasteur. The General Meeting of Shareholders of Aventis Pasteur, held in December 2004, voted the change in name from Aventis Pasteur to sanofi pasteur. The Aventis Pasteur MSD joint venture, equally owned by Aventis Pasteur and Merck & Co. Inc.
Jean-François DEHECQ, Chairman and CEO of Sanofi-aventis, is currently accompanying Philippe DOUSTE-BLAZY, French Minister for Humanitarian aid, Health and the Family in his mission to Colombo, Sri-Lanka, to provide six tons of Sanofi-aventis medicines, consisting of 70,000 packs of antibiotics, anti-diarrhea medicines and antibacterial treatments. Within the framework of a humanitarian initia
Sanofi-aventis announced today its plan to reimburse the short-term tranche of the syndicated credit line which was put in place in April 2004 to finance the acquisition of Aventis (Tranche A). This 5 billion-Euro tranche is maturing on January 24, 2005. The company had an option to extend maturity for a maximum of one year. However, in order to optimise its financing costs, sanofi-aventis has
Sequential Taxotere following epirubicin-based regimen demonstrates survival advantage Aventis, part of the sanofi-aventis Group announced today that the results of a large phase III study demonstrated that sequential TAXOTERE (docetaxel) Injection Concentrate-based regimen significantly improved overall survival of women with operable, node-positive early stage breast cancer compared to a s
